Methylphenidate for gait impairment in Parkinson disease: a randomized clinical trial. - Wikidata - awgldk - TriplyDB

Methylphenidate for gait impairment in Parkinson disease: a randomized clinical trial.

Methylphenidate for gait impairment in Parkinson disease: a randomized clinical trial.

http://www.wikidata.org/entity/Q34743145

about

Postural instability in patients with Parkinson's disease. Epidemiology, pathophysiology and management.Treatment of cognitive, psychiatric, and affective disorders associated with Parkinson's disease.New treatments for the motor symptoms of Parkinson's disease.Intravenous amantadine for freezing of gait resistant to dopaminergic therapy: a randomized, double-blind, placebo-controlled, cross-over clinical trial.Monoamine reuptake inhibitors in Parkinson's disease.Parkinson's disease therapeutics: new developments and challenges since the introduction of levodopa.Non-dopamine receptor ligands for the treatment of Parkinson's disease. Insight into the related chemical/property space.Efficacy of exercise intervention programs on cognition in people suffering from multiple sclerosis, stroke and Parkinson's disease: A systematic review and meta-analysis of current evidence.The Effects of Methylphenidate on Resting-State Functional Connectivity of the Basal Nucleus of Meynert, Locus Coeruleus, and Ventral Tegmental Area in Healthy Adults.Freezing of Gait in Parkinsonism and its Potential Drug Treatment.Treatment of Parkinson's disease: what's in the non-dopaminergic pipeline?Normal and pathological gait: what we learn from Parkinson's disease.Drug treatments for the neuropsychiatric complications of Parkinson's disease.Freezing of gait in Parkinson's disease: where are we now?Non-dopaminergic treatments for motor control in Parkinson's disease.Clinical syndromes: Parkinsonian gait.What are the priorities in Parkinson's disease clinical research? A focus on motor complications, gait and cognition.Norepinephrine deficiency in Parkinson's disease: the case for noradrenergic enhancement.Nondopaminergic treatments for Parkinson's disease: current and future prospects.Pharmacological treatment in Parkinson's disease: Effects on gait.Freezing of gait in Parkinson's disease: from pathophysiology to emerging therapies.Gait function and locus coeruleus Lewy body pathology in 51 Parkinson's disease patients.Advances in Therapeutic Options for Gait and Balance in Parkinson's Disease Methylphenidate : a treatment for Parkinson's disease?ExPPNing how acetylcholine improves gait in Parkinson's disease: An Editorial Highlight for 'Deletion of the Vesicular Acetylcholine Transporter from Pedunculopontine/laterodorsal tegmental neurons modifies gait'.Motor Complications of Dopaminergic Medications in Parkinson's Disease.

P2860

Q34306751-E220B406-525E-48DA-B8BF-A9AA57F937E6 Q34388686-C31A4C84-DEF0-4A70-B376-2202958E72B9 Q34443682-281DB044-BDE0-4FBF-A7D5-A63E6053F716 Q34489770-4419DECC-15D8-4E6E-9E8C-B5459B707B4B Q35165280-9C724D3C-9F7E-4D9C-AF88-6D4108894A27 Q35614156-451CC26E-BA88-4265-B12B-2E1A4415EAE4 Q35625767-8F9C144D-3C4D-45CE-B076-0571A2D0EFB3 Q35814149-80CB99E1-57AB-44EA-9250-1B4AD8535CB3 Q36805793-159CEFE8-297F-4768-8EAD-80748CA136A3 Q36925884-C7390F8F-820C-4FDD-90F5-511979799F3C Q37506507-B35B7133-A37F-43AD-97B1-DDC502939A0C Q38023268-D40CF58B-19F6-4A72-9940-958C1BC04889 Q38067142-7C087620-6ED0-461D-AED8-86554F2E6DB8 Q38102609-8B79D70F-98B6-4353-B0CF-F06141C42B52 Q38126817-86D6BD7A-9530-4FE4-AC23-A551EE858EA4 Q38153328-B22799DB-CA37-4DBB-A631-15F0EDD0CA99 Q38212033-A05B6FE2-9E14-42EF-8609-FFBBB2A70BBE Q38258228-A1DD4E82-6AE0-45CB-A70D-DDEA02CEC62F Q38845546-282649F7-7E8E-4802-8BD0-570ABEBA36DC Q38909702-55201FE0-DE02-4BEF-AC16-9C32F3FE5EBB Q38947418-D35FD1CB-179A-4403-B479-C30EC4F69A0F Q39332170-1715AAE3-A5CA-43EB-A1DE-39EAB24FFB5B Q39692778-614E32C0-D920-457A-A53B-D89B51906FD6 Q48290666-640A04F5-9F36-4ADA-BE8B-4FA25F158F0B Q48370307-2682D9FF-74DD-4BB2-AC10-3E31A8DC7221 Q55279095-48DEEBB8-E94A-44CA-8811-A380FF5037E2

P2860

Methylphenidate for gait impairment in Parkinson disease: a randomized clinical trial.

http://www.wikidata.org/entity/Q34743145

description

2011 nî lūn-bûn

@nan

2011 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Methylphenidate for gait impairment in Parkinson disease: a randomized clinical trial.

@ast

Methylphenidate for gait impairment in Parkinson disease: a randomized clinical trial.

@en

Methylphenidate for gait impairment in Parkinson disease: a randomized clinical trial.

@nl

type

label

Methylphenidate for gait impairment in Parkinson disease: a randomized clinical trial.

@ast

Methylphenidate for gait impairment in Parkinson disease: a randomized clinical trial.

@en

Methylphenidate for gait impairment in Parkinson disease: a randomized clinical trial.

@nl

prefLabel

Methylphenidate for gait impairment in Parkinson disease: a randomized clinical trial.

@ast

Methylphenidate for gait impairment in Parkinson disease: a randomized clinical trial.

@en

Methylphenidate for gait impairment in Parkinson disease: a randomized clinical trial.

@nl

P1433

Q34743145-84C38807-8B91-4AB7-BF15-AD86752EFC5B

P1476

Q34743145-CA77F51B-E6F4-46B4-9752-0E883FA3941C

P2093

Q34743145-22E2BBD6-7504-4B57-8AC6-EB5DD9DDB976

Q34743145-2A69CBA3-4C46-448E-AA5E-107DF37D0C72

Q34743145-3C3AB83C-C98D-4E50-8253-E080E7F53955

Q34743145-548B2CCE-16CC-4F8D-AAE7-C722BEC65202

Q34743145-7DE19500-1234-4CD5-9173-690FCF1E0D42

Q34743145-8B0B85AA-19A0-4E50-AD2B-FECFF82BDCE3

Q34743145-940D42F1-D3DD-4655-BD12-D938A543D280

Q34743145-9F2FA253-B845-452A-90F4-DC8FA66B5751

Q34743145-AA10D8A9-BF85-4505-8BDF-5752DCC16236

Q34743145-D09E5312-6EDA-4CEE-9228-0882DE1F3509

P2860

Q34743145-02BDEF41-25B2-444E-A62E-07DA0F4D8616

Q34743145-16D75132-FBE2-421C-B804-930259C948D8

Q34743145-35C05602-3715-4F23-8650-04D84124FE50

Q34743145-3D5F8999-7B2A-440A-BB75-5EBF2B0340D5

Q34743145-3F202D67-C14C-4E0C-A5DB-D7571E619D2D

Q34743145-49E24CC0-3228-48B3-9693-2C7A476229F0

Q34743145-53825537-D9D9-471B-92C4-CB875EFC94DE

Q34743145-59590847-3F22-4944-A14E-6CD3BBF43B20

Q34743145-68BA2F5D-35C0-477A-AF51-0174DC53A2A9

Q34743145-A86718DF-C791-4CFE-8979-4958F8C0546C

P304

Q34743145-7FCA56B9-341A-4B39-B218-32544132F1D5

P31

Q34743145-201DA2E2-A283-47C8-A972-D55077C69961

P356

Q34743145-8695B194-E749-49CB-8BF3-AAF895503518

P407

Q34743145-52FFF097-A9FA-4515-A386-8953C1134DD9

P433

Q34743145-3E16F8D2-6303-4B04-A213-DA7C0162CCBA

P478

Q34743145-80E9995F-2F65-4CDB-AB67-ED9F96EB7A08

P577

Q34743145-1C048ADB-3DA8-406A-BA74-949639F09B04

P5875

Q34743145-EA5167B7-13F1-42DC-9049-68D759592334

P698

Q34743145-ABD14561-BDF0-4619-8F8D-2CADEC1CA0EB

P921

Q34743145-A8049F4F-D613-4049-BBC1-08493086C4D7

P932

Q34743145-B8A64FFC-CAF9-4035-AC7C-043D617E0EF6

P356

WNL.0B013E3182143537

P1433

P1476

Methylphenidate for gait impairment in Parkinson disease: a randomized clinical trial.

@en

P2093

A J Espay

http://www.w3.org/2001/XMLSchema#string

A K Dwivedi

http://www.w3.org/2001/XMLSchema#string

A P Duker

http://www.w3.org/2001/XMLSchema#string

A Sahay

http://www.w3.org/2001/XMLSchema#string

B N Maddux

http://www.w3.org/2001/XMLSchema#string

F J Revilla

http://www.w3.org/2001/XMLSchema#string

J E Vaughan

http://www.w3.org/2001/XMLSchema#string

J T Slevin

http://www.w3.org/2001/XMLSchema#string

L Gaines

http://www.w3.org/2001/XMLSchema#string

M Gartner

http://www.w3.org/2001/XMLSchema#string

P2860

A SELF-RATING DEPRESSION SCALE

Parkinsonism: onset, progression and mortality

Core assessment program for intracerebral transplantations (CAPIT)

A new depression scale designed to be sensitive to change

Cerebral cortical and subcortical cholinergic deficits in parkinsonian syndromes

Methylphenidate (OROS formulation).

Relative sensitivity of the Montgomery-Asberg Depression Rating Scale, the Hamilton Depression rating scale and the Clinical Global Impressions rating scale in antidepressant clinical trials.

The EQ-5D--a generic quality of life measure-is a useful instrument to measure quality of life in patients with Parkinson's disease.

Improvement of gait by chronic, high doses of methylphenidate in patients with advanced Parkinson's disease

Evolution of cognitive dysfunction in an incident Parkinson's disease cohort.

P304

1256-1262

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1212/WNL.0B013E3182143537

http://www.w3.org/2001/XMLSchema#string

P407

P433

14

http://www.w3.org/2001/XMLSchema#string

P478

76

http://www.w3.org/2001/XMLSchema#string

P577

2011-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

50999691

http://www.w3.org/2001/XMLSchema#string

P698

21464430

http://www.w3.org/2001/XMLSchema#string

P921

Parkinson's disease

P932

3068005

http://www.w3.org/2001/XMLSchema#string